Verona Pharma PLC
VRNA65.460USD
+0.679+1.05%
收盤 04/25, 16:00（美東）報價延遲15分鐘
44.32B總市值
虧損本益比TTM
關於 Verona Pharma PLC 公司
Verona Pharma Plc 是一家總部位於英國的生物製藥公司。該公司專注於開發和商業化用於治療未滿足醫療需求的呼吸系統疾病的療法。其候選產品恩替芬鹼是一種研究性吸入小分子酶，可雙重抑制酶的磷酸二酯酶 3 和 4 (PDE3 和 PDE4)，將支氣管擴張劑和非甾體抗炎活性結合在一個化合物中。該公司致力於開發用於治療慢性阻塞性肺病 (COPD) 的吸入恩替芬鹼。該公司的另外兩種恩替芬鹼配方正處於用於治療 COPD 的 II 期開發階段：乾粉吸入器 (DPI) 和加壓定量吸入器 (pMDI)。該公司的全資子公司是 Verona Pharma, Inc.
公司簡介
公司代碼VRNA
公司名稱Verona Pharma PLC
上市日期Mar 30, 2005
成立日期2005
CEODr. David S. Zaccardelli
員工數量209
證券類型Depository Receipt
年結日Mar 30
公司地址Riverside
城市LONDON
上市交易所NASDAQ Global Market Consolidated
國家United Kingdom
郵編SE1 2RE
電話442032834200
網址https://www.veronapharma.com/
公司代碼VRNA
上市日期Mar 30, 2005
成立日期2005
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.51M
+1.80K%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.60M
+4.02K%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Director
Non-Executive Director
--
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Director
Non-Executive Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.51M
+1.80K%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.60M
+4.02K%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 3月28日 週五
更新時間: 3月28日 週五
持股股東
股東類型
持股股東
股東統計
佔比
Zaccardelli (David S)
13.55%
Hahn (Mark W)
12.48%
Perceptive Advisors LLC
7.52%
New Enterprise Associates (NEA)
4.81%
Frazier Life Sciences Management, L.P.
3.98%
Other
57.67%
持股股東
股東統計
佔比
Zaccardelli (David S)
13.55%
Hahn (Mark W)
12.48%
Perceptive Advisors LLC
7.52%
New Enterprise Associates (NEA)
4.81%
Frazier Life Sciences Management, L.P.
3.98%
Other
57.67%
股東類型
股東統計
佔比
Individual Investor
35.16%
Investment Advisor/Hedge Fund
22.11%
Hedge Fund
21.55%
Investment Advisor
15.58%
Private Equity
11.64%
Venture Capital
7.78%
Research Firm
2.44%
Family Office
1.04%
Bank and Trust
0.28%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
341
98.98M
116.47%
+16.60M
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
2022Q4
162
65.88M
87.36%
-542.66K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Zaccardelli (David S)
11.51M
13.55%
+10.91M
+1.80K%
Mar 01, 2025
Hahn (Mark W)
10.60M
12.48%
+10.34M
+4.02K%
Mar 01, 2025
Perceptive Advisors LLC
6.39M
7.52%
+76.17K
+1.21%
Dec 31, 2024
New Enterprise Associates (NEA)
4.08M
4.81%
-1.50M
-26.86%
Jan 16, 2025
Frazier Life Sciences Management, L.P.
3.38M
3.98%
--
--
Dec 31, 2024
Ali (Behbahani)
3.19M
3.76%
+3.19M
--
Jan 16, 2025
Eventide Asset Management, LLC
3.13M
3.69%
+706.28K
+29.11%
Dec 31, 2024
Maverick Capital, Ltd.
3.13M
3.68%
-1.09M
-25.79%
Dec 31, 2024
Wellington Management Company, LLP
3.03M
3.56%
+1.15M
+61.03%
Dec 31, 2024
Vivo Capital, LLC
2.28M
2.69%
-1.27M
-35.66%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
AdvisorShares Dorsey Wright ADR ETF
6.2%
ALPS Medical Breakthroughs ETF
4.7%
ProShares Ultra Nasdaq Biotechnology
0.5%
First Trust IPOX Europe Equity Opportunities ETF
0.49%
Invesco Nasdaq Biotechnology ETF
0.49%
iShares Biotechnology ETF
0.3%
Goldman Sachs Innovate Equity ETF
0.16%
Eventide US Market ETF
0.09%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Long/Short Equity ETF
0%
查看更多
AdvisorShares Dorsey Wright ADR ETF
佔比6.2%
ALPS Medical Breakthroughs ETF
佔比4.7%
ProShares Ultra Nasdaq Biotechnology
佔比0.5%
First Trust IPOX Europe Equity Opportunities ETF
佔比0.49%
Invesco Nasdaq Biotechnology ETF
佔比0.49%
iShares Biotechnology ETF
佔比0.3%
Goldman Sachs Innovate Equity ETF
佔比0.16%
Eventide US Market ETF
佔比0.09%
Fidelity Nasdaq Composite Index ETF
佔比0.01%
First Trust Long/Short Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據